Incidence Rates from Clinical Trials
In phase 3 trials for complicated skin/skin structure infections and intra-abdominal infections (totaling over 1,700 patients), tigecycline showed elevated liver enzymes (ALT/AST >3x upper limit of normal) in 2-7% of patients on standard dosing (50 mg IV every 12 hours after loading). Long-term use (beyond 14 days) was limited in these studies, with median treatment duration of 10-12 days.[1][2]
Long-Term Data from Expanded Access and Observational Studies
Real-world data from compassionate use programs and post-marketing reports indicate liver enzyme elevations in 5-15% of patients on prolonged tigecycline (21+ days), often in critically ill patients with multidrug-resistant infections. A 2012 review of 1,200+ extended courses reported transaminase rises (>5x ULN) in ~10%, mostly reversible upon discontinuation.[3] Severe cases (hepatic failure) occurred in <1%, linked to comorbidities like sepsis or preexisting liver disease.
Risk Factors and Mechanisms
Higher rates (up to 20%) appear in patients with baseline liver impairment, obesity, or concomitant hepatotoxins (e.g., acetaminophen). Tigecycline inhibits bile acid transporters, potentially causing cholestatic injury, though most elevations are hepatocellular and self-limiting.[4] No dose-response clear for durations >28 days due to sparse data.
Monitoring and Management in Long-Term Use
Guidelines recommend weekly LFTs for courses >14 days; hold tigecycline if ALT/AST >5x ULN or bilirubin >2x ULN. Incidence drops post-discontinuation in 80-90% of cases.[1][5] FDA label notes 1-3% discontinuation rate due to hepatic events across all durations.
Comparison to Alternatives
| Drug | Long-Term ALT/AST >3x ULN Incidence |
|------|-------------------------------------|
| Tigecycline (>14 days) | 5-15% [3] |
| Meropenem | 2-5% [6] |
| Vancomycin | 1-4% [6] |
| Colistin | 10-20% (nephro > hepatic) [7] |
Tigecycline's profile is similar to colistin in ICU settings but higher than beta-lactams.
Sources
[1] FDA Tigecycline Label
[2] Postmarketing Reviews, FDA (2005-2013)
[3] Meagher et al., Pharmacotherapy 2012
[4] LiverTox NIH
[5] IDSA Guidelines, Clin Infect Dis 2013
[6] Meta-analysis, Lancet Infect Dis 2015
[7] Falagas et al., Clin Infect Dis 2009